PMID- 38184121
OWN - NLM
STAT- MEDLINE
DCOM- 20240508
LR  - 20240508
IS  - 1638-6183 (Electronic)
IS  - 0300-9084 (Linking)
VI  - 220
DP  - 2024 May
TI  - The determinants of metabolic discrepancies in aerobic glycolysis: Providing 
      potential targets for breast cancer treatment.
PG  - 107-121
LID - S0300-9084(24)00003-8 [pii]
LID - 10.1016/j.biochi.2024.01.003 [doi]
AB  - Altered aerobic glycolysis is the robust mechanism to support cancer cell 
      survival and proliferation beyond the maintenance of cellular energy metabolism. 
      Several investigators portrayed the important role of deregulated glycolysis in 
      different cancers, including breast cancer. Breast cancer is the most ubiquitous 
      form of cancer and the primary cause of cancer death in women worldwide. Breast 
      cancer with increased glycolytic flux is hampered to eradicate with current 
      therapies and can result in tumor recurrence. In spite of the low order 
      efficiency of ATP production, cancer cells are highly addicted to glycolysis. The 
      glycolytic dependency of cancer cells provides potential therapeutic strategies 
      to preferentially kill cancer cells by inhibiting glycolysis using antiglycolytic 
      agents. The present review emphasizes the most recent research on the implication 
      of glycolytic enzymes, including glucose transporters (GLUTs), hexokinase (HK), 
      phosphofructokinase (PFK), pyruvate kinase (PK), lactate dehydrogenase-A (LDHA), 
      associated signalling pathways and transcription factors, as well as the 
      antiglycolytic agents that target key glycolytic enzymes in breast cancer. The 
      potential activity of glycolytic inhibitors impinges cancer prevalence and 
      cellular resistance to conventional drugs even under worse physiological 
      conditions such as hypoxia. As a single agent or in combination with other 
      chemotherapeutic drugs, it provides the feasibility of new therapeutic modalities 
      against a wide spectrum of human cancers.
CI  - Copyright (c) 2024 Elsevier B.V. and Societe Francaise de Biochimie et Biologie 
      Moleculaire (SFBBM). All rights reserved.
FAU - Littleflower, Ajeesh Babu
AU  - Littleflower AB
AD  - Division of Cancer Research, Regional Cancer Centre (Research Centre, University 
      of Kerala), Thiruvananthapuram, Kerala, 695011, India.
FAU - Parambil, Sulfath Thottungal
AU  - Parambil ST
AD  - Division of Cancer Research, Regional Cancer Centre (Research Centre, University 
      of Kerala), Thiruvananthapuram, Kerala, 695011, India.
FAU - Antony, Gisha Rose
AU  - Antony GR
AD  - Division of Cancer Research, Regional Cancer Centre (Research Centre, University 
      of Kerala), Thiruvananthapuram, Kerala, 695011, India.
FAU - Subhadradevi, Lakshmi
AU  - Subhadradevi L
AD  - Division of Cancer Research, Regional Cancer Centre (Research Centre, University 
      of Kerala), Thiruvananthapuram, Kerala, 695011, India. Electronic address: 
      rcc.lakshmi@gmail.com.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20240104
PL  - France
TA  - Biochimie
JT  - Biochimie
JID - 1264604
RN  - 0 (Antineoplastic Agents)
RN  - EC 2.7.1.1 (Hexokinase)
RN  - 0 (Glucose Transport Proteins, Facilitative)
SB  - IM
MH  - Humans
MH  - *Breast Neoplasms/metabolism/drug therapy/pathology
MH  - Female
MH  - *Glycolysis/drug effects
MH  - Warburg Effect, Oncologic/drug effects
MH  - Antineoplastic Agents/therapeutic use/pharmacology
MH  - Hexokinase/metabolism/antagonists & inhibitors
MH  - Glucose Transport Proteins, Facilitative/metabolism
OTO - NOTNLM
OT  - Aerobic glycolysis
OT  - Anti-glycolytic agents
OT  - Breast cancer
OT  - Glucose metabolism
OT  - Glycolytic enzymes
OT  - Targeted therapy
COIS- Declaration of competing interest The authors have no conflict of interest with 
      the contents of this article.
EDAT- 2024/01/07 06:44
MHDA- 2024/05/09 00:48
CRDT- 2024/01/06 19:14
PHST- 2023/08/10 00:00 [received]
PHST- 2023/12/22 00:00 [revised]
PHST- 2024/01/03 00:00 [accepted]
PHST- 2024/05/09 00:48 [medline]
PHST- 2024/01/07 06:44 [pubmed]
PHST- 2024/01/06 19:14 [entrez]
AID - S0300-9084(24)00003-8 [pii]
AID - 10.1016/j.biochi.2024.01.003 [doi]
PST - ppublish
SO  - Biochimie. 2024 May;220:107-121. doi: 10.1016/j.biochi.2024.01.003. Epub 2024 Jan 
      4.